SCHEMBL1993439

SCHEMBL1993439

CCn1cnc2c(=O)n(-c3ccc(Cl)cc3)c(N3CCCC(Cc4ccccc4)C3)nc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.42
MAPK1 P28482 4/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
NPSR1 Q6W5P4 3/20 0.42
TSHR P16473 3/20 0.42
CYP2D6 P10635 2/20 0.42
KDM4E B2RXH2 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
GAA P10253 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
CYP2C19 P33261 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MAPT P10636 4/20 0.40
LMNA P02545 3/20 0.40
DPP4 P27487 3/20 0.40
HTT P42858 1/20 0.39
PRKDC P78527 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1989825 0.87 ALDH1A1 (0.44) ALDH1A1MAPK1MEN1KMT2ANPSR1
SCHEMBL2000177 0.85 ALDH1A1 (0.44) ALDH1A1MAPK1MEN1KMT2ANPSR1
SCHEMBL1996845 0.84 ALDH1A1 (0.41) ALDH1A1MAPK1MEN1KMT2ANPSR1
SCHEMBL1991529 0.83 KDM4E (0.38) ALDH1A1MAPK1MEN1KMT2ANPSR1
SCHEMBL1990704 0.83 KDM4E (0.38) ALDH1A1MAPK1MEN1KMT2ANPSR1
SCHEMBL1997995 0.83 ALDH1A1 (0.48) ALDH1A1MAPK1MEN1KMT2ANPSR1
SCHEMBL1994613 0.79 MAP4K4 (0.42) ALDH1A1MAPK1MEN1KMT2ANPSR1
SCHEMBL1998159 0.79 CNR2 (0.38) ALDH1A1MAPK1MEN1KMT2ANPSR1
SCHEMBL1989184 0.78 MEN1 (0.35) ALDH1A1MAPK1MEN1KMT2ANPSR1
SCHEMBL4427346 0.76 DRD1 (0.53) MAPK1MEN1KMT2ANPSR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1866310-B1 2,3-SUBSTITUTED FUSED PYRIMIDIN-4(3H)-ONES AS VR1 ANTAGONISTS MERCK SHARP & DOHME (GB) 2012-07-11 EP disclosed
US-20110152242-A1 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists MERCK SHARP & DOHME LTD. (GB) 2011-06-23 US disclosed
EP-1866310-A1 2,3-SUBSTITUTED FUSED PYRIMIDIN-4(3H)-ONES AS VR1 ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2007-12-19 EP disclosed
WO-2006100520-A1 2,3-SUBSTITUTED FUSED PYRIMIDIN-4(3H)-ONES AS VR1 ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152242-A1 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists NR2C2, NR3C2, NR2E3 ALDH1A1 1796/4885MAPK1 2356/4885MEN1 3443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.